Provectus Biopharmaceuticals Announces Abstract Av
Post# of 22759
Posted On: 11/06/2014 4:09:25 PM
Provectus Biopharmaceuticals Announces Abstract Available on Intralesional PV-10 and Co-inhibitory Blockade Data for SITC 29th Annual Meeting
Thursday November 6, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting is now available at http://www.immunotherapyofcancer.org/content/2/S3/P120. The poster concludes that certain studies "support the induction of increased tumor-specific immunity after co-inhibitory blockade in combination with IL PV-10 therapy."
Dr Shari Pilon-Thomas of the Moffitt Cancer Center will present this abstract in two time slots on Saturday, November 8: 12:30 to 2:00 pm and 6:00 to 7:30 pm. The SITC 29th Annual Meeting opens today in National Harbor, Maryland, and runs through November 9, 2014.
The complete press release is available at www.pvct.com/pressrelease.html?article=20141106.2 on the Provectus website.
Thursday November 6, 2014
KNOXVILLE, Tenn.--(BUSINESS WIRE)--Provectus Biopharmaceuticals, Inc. (NYSE MKT: PVCT, www.pvct.com), a development-stage oncology and dermatology biopharmaceutical company ("Provectus"
, announced today that the abstract titled "Efficacy of Intralesional Injection with PV-10 in Combination with Co-Inhibitory Blockade in a Murine Model of Melanoma," to be presented at the Society for Immunotherapy of Cancer [SITC] 29th Annual Meeting is now available at http://www.immunotherapyofcancer.org/content/2/S3/P120. The poster concludes that certain studies "support the induction of increased tumor-specific immunity after co-inhibitory blockade in combination with IL PV-10 therapy." Dr Shari Pilon-Thomas of the Moffitt Cancer Center will present this abstract in two time slots on Saturday, November 8: 12:30 to 2:00 pm and 6:00 to 7:30 pm. The SITC 29th Annual Meeting opens today in National Harbor, Maryland, and runs through November 9, 2014.
The complete press release is available at www.pvct.com/pressrelease.html?article=20141106.2 on the Provectus website.
(0)
(0)
I'm in it to win it!
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
NASDAQ DIP and RIP
Here is the best word that describes what i do here.
Intuitive;
means having the ability to understand or know something without any direct evidence or reasoning process.
I was born with it, I'm truly blessed!
Alway's searching for winners'
Scroll down for more posts ▼